Assignee
MAGENTA THERAPEUTICS INC
US·14 granted patents·42 pending applications·57 citations·filing 2014–2023
Top patents by PatentIndex Score
56 records- 0192US10899843B2Compositions and methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Jan 26, 2021·8 cites·38 claims
- 0291US10882915B2Compositions and methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Jan 5, 2021·9 cites·27 claims
- 0389US11572411B2Anti-CD117 antibodies and conjugatesMAGENTA THERAPEUTICS INC·Filed 2020·Granted Feb 7, 2023·2 cites·14 claims
- 0489US10351572B2Aryl hydrocarbon receptor antagonists and uses thereofMAGENTA THERAPEUTICS INC·Filed 2019·Granted Jul 16, 2019·5 cites·28 claims
- 0589US10111966B2Methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2017·Granted Oct 30, 2018·12 cites·16 claims
- 0686US10058573B1Dosing regimens for the mobilization of hematopoietic stem cellsMAGENTA THERAPEUTICS INC·Filed 2017·Granted Aug 28, 2018·7 cites·9 claims
- 0785US11229711B2Linkers for antibody-drug conjugates and related compounds, compositions, and methods of useMAGENTA THERAPEUTICS INC·Filed 2014·Granted Jan 25, 2022·3 cites·5 claims
- 0884US10919900B2Aryl hydrocarbon receptor antagonists and uses thereofMAGENTA THERAPEUTICS INC·Filed 2019·Granted Feb 16, 2021·1 cites·16 claims
- 0984US10781259B2Modified antibodies and related compounds, compositions, and methods of useMAGENTA THERAPEUTICS INC·Filed 2014·Granted Sep 22, 2020·3 cites·29 claims
- 1084US10624973B2Methods for the depletion of cellsMAGENTA THERAPEUTICS INC·Filed 2019·Granted Apr 21, 2020·2 cites·26 claims
- 1181US10457683B2Aryl hydrocarbon receptor antagonists and uses thereofMAGENTA THERAPEUTICS INC·Filed 2018·Granted Oct 29, 2019·2 cites·20 claims
- 1280US2024207428A1Compositions and methods for the depletion of cellsMAGENTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1379US10434185B2Compositions and methods for the depletion of CD137+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Oct 8, 2019·1 cites·29 claims
- 1477US11260079B2Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2019·Granted Mar 1, 2022·1 cites·23 claims
- 1575US10576161B2Compositions and methods for the depletion of CD137+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Mar 3, 2020·1 cites·24 claims
- 1672US2023130646A1Dosing regimens for the mobilization of hematopoietic stem cellsMAGENTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1768US2021179625A1Aryl hydrocarbon receptor antagonists and uses thereofMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1867US2020392108A1Antibody-drug conjugates and related compounds, compositions and methodsMAGENTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1966US2023109312A1Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of useMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2066US2024075157A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2165US2020376134A1Compositions and methods for the depletion of cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2264US2023414565A1Compositions and methods for treating hematological malignanciesMAGENTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2363US2021162063A1Compositions and methods for the depletion of cd117+ cellsMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2463US2019328901A1Compositions and methods for the depletion of cellsMAGENTA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2563US2022096559A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2660US2020276326A1Compositions and methods for the depletion of cd5+ cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2760US2019336536A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2859US2020289664A1Compositions and methods for the depletion of cd137+ cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2956US2023330185A1Methods and compositions for transducing hematopoietic stem and progenitor cells in vivoMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3056US2019167726A1Dosing Regimens for the Mobilization of Hematopoietic Stem CellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3156US2021283267A1Therapeutic methods using antibody drug conjugates (adcs)MAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3256US2022177578A1Anti-cd117 antibodies and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3356US2022177575A1Anti-cd117 antibodies and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3456US2022175946A1Conditioning methods for gene therapyMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3555US2021379113A1Methods for hematopoietic stem and progenitor cell transplant therapyMAGENTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3654US2020376135A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3754US2023183344A1T-cell bispecific binding proteinsMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3853US2022249683A1T-cell depleting therapiesMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3953US2019134217A1Compositions and methods for the depletion of cd117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4053US2022175944A1Anti-cd117 antibody-drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4153US2021260212A1Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapyMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4253US2021379033A1Methods of treating cancer with aryl hydrocarbon receptor antagonistsMAGENTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4352US2022226493A1Anthracycline antibody-drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4452US2023390412A1Compositions and methods for allogeneic transplantationMAGENTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4552US2021095039A1Anti-cd252 antibodies, conjugates, and methods of useMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4652US2022401481A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4751US2022175951A1Anti-CD45 Antibody Drug Conjugates and Uses ThereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4850US2022177577A1Anti-cd117 antibody drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4950US2022062339A1Use of an anti-cd45 antibody drug conjugate (adc) in cell therapyMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 5049US2019343885A1Compositions and methods for hematopoietic stem and progenitor cell transplant therapyMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when MAGENTA THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →